Background
Two-dose vaccination using the MVA-BN vaccine reduces the risk of Mpox among at-risk populations. However, breakthrough cases of Mpox were reported among individuals with suboptimal antibody responses.
Methods
This prospective observational study enrolled MSMs scheduled to undergo 2 doses of MVA-BN vaccination to investigate the serological responses. Blood samples were collected at months 1, 3, 6, 12, 18, and 24 after the second dose for determinations of anti-A29 and anti-H3 IgG. The primary endpoints were the seropositivity rates of anti-A29 and anti-H3 IgG 2 years after the second dose of vaccination. Secondary outcomes included the serological responses at each time point and occurrence of Mpox during the 2-year observation.
Results
425 participants who had completed 2-dose MVA-BN vaccination were included, including 277 (65.2%) people with HIV (PWH) and 148 (34.8%) people without HIV (PWoH). Among PWH, PWoH, and individuals with prior smallpox vaccination, the seropositivity rate for anti-A29 on the 3rd month after the second dose of vaccination was 16.3%, 8.6% and 49.3%, respectively, and that for anti-H3 IgG was 55.5%, 54.7% and 88.1%, respectively. After 2-year observation (figure), the seropositivity rates among the 3 groups were 35.8%, 36.5% and 63.2%, respectively, for anti-A29, and 20.3%, 21.5% and 68.4%, respectively, for anti-H3 IgG. The only factor associated with loss of serologic response for anti-H3 IgG after 2-year observation was history of smallpox vaccination (aOR, 0.12; 95% CI, 0.05-0.28) after adjustments. Two PWH without prior smallpox vaccination developed Mpox 10 and 24 months, respectively, after they had received two doses of MVA-BN vaccination; neither had anti-A29 and anti-H3 IgG seroconversion. In addition, 17 other individuals had a ≥4-fold increase of both anti-A29 and anti-H3 IgG titer during follow-up, suggesting asymptomatic Mpox infection. The median interval between the second dose of vaccination and seroconversion were 20 months (IQR, 17-22 months). In Cox regression model, those who acquired sexually transmitted infections were more likely to have a ≥4-fold increase of both anti-A29 and anti-H3 IgG or breakthrough Mpox infection (HR, 2.56; 95% CI, 0.85-7.71).
Conclusions
We found that anti-A29 and anti-H3L antibodies declined following MVA-BN vaccination. Breakthrough Mpox infections may occur in vaccine non-responders and responders, suggesting that active surveillance is warranted.
Table or Figure
